Griffonilide is primarily investigated for its potential anti-inflammatory and neuroprotective properties. It has shown promise in preclinical studies targeting neurodegenerative conditions such as Alzheimer’s and Parkinson’s diseases, where it may help reduce oxidative stress and inhibit key inflammatory pathways in the brain. Its ability to cross the blood-brain barrier enhances its suitability for central nervous system therapies. Additionally, griffonilide exhibits antimicrobial activity against certain Gram-positive bacteria, suggesting possible use in treating bacterial infections. Research is ongoing to explore its efficacy in cancer models, particularly in modulating apoptosis in tumor cells. Due to its natural origin and structural complexity, it also serves as a lead compound for the development of synthetic analogs with improved pharmacokinetic profiles.